# US 2016/0257664 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257664 A1
- Document ID: US20160257664A1
- Status: Published application
- Kind: A1
- Application number: 15/031,323
- Filed: 2014-10-23
- Published: 2016-09-08
- Earliest claimed: 2013-10-25
- Assignees: GlaxoSmithKline LLC
- Applicants: Glaxosmithkline LLC
- Inventors: Veronique BIRAULT; Amanda Jennifer CAMPBELL; Stephen Anthony HARRISON; Joelle LE
- Web page: https://patentgrep.com/patent/US20160257664A1

## CPC

- C07D 309/06: Radicals substituted by oxygen atoms
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is directed to crystalline forms of a compound which has retinoid-related orphan receptor gamma (RORγ) modulator activity, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.

## Claims

### Claim 1

A crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

### Claim 2 (depends on 1)

The crystalline form according to claim 1 which is an anhydrous crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

### Claim 3 (depends on 2)

The crystalline form according to claim 2 having an XRPD with characteristic 2 theta angle peaks at 4.3±0.1, 8.6±0.1 and 10.2±0.1.

### Claim 4 (depends on 2)

The crystalline form according to claim 2 characterised by a DSC trace with an onset temperature of approximately 90.8° C.

### Claim 5 (depends on 1)

The crystalline form according to claim 1 which is a hydrated crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

### Claim 6 (depends on 5)

The crystalline form according to claim 5 having an XRPD with characteristic 2 theta angle peaks at 7.8±0.1 and 20.1±0.1.

### Claim 7 (depends on 5)

The crystalline form according to claim 5 characterised by a DSC trace with an onset temperature of approximately 50.4° C.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide according to claim 1, and a pharmaceutically acceptable excipient.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method of treatment of an inflammatory, metabolic or autoimmune disease mediated by RORγ in a human in need thereof comprising administering to said human an effective amount of the crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide according to claim 1.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the inflammatory, metabolic or autoimmune disease disease mediated by RORγ is selected from asthma, chronic obstructive pulmonary disease, bronchitis, allergic diseases, allergic rhinitis, atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile Rheumatoid arthritis, Osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, acne, psoriasis, Hashimoto's disease, pancreatisis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, inflammatory bowel disease, inflammatory bowel syndrome, Sjorgen's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, uveitis, Guillain-Barre syndrome, psoriatic arthritis, Graves' disease or scleritis.

### Claim 15

(canceled)

### Claim 16 (depends on 11)

A process for preparing the pharmaceutical composition according to claim 11, which process comprises bringing the crystalline form into association with the pharmaceutically acceptable excipient.

### Claim 17 (depends on 1)

A process for preparing the crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide according to claim 1 comprising the steps of
(a) adding N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide to a mixture of water and an organic solvent,
(b) stirring the resulting mixture for several days while cycling the temperature, and
(c) collecting the resulting solids by filtration.

### Claim 18 (depends on 1)

A method of treating psoriasis in a human in need thereof comprising administering to said human an effective amount of the crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide according to claim 1.

### Claim 19 (depends on 1)

A method of treating acne in a human in need thereof comprising administering to said human an effective amount of the crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide according to claim 1.
